A cell-permeable nanobody to restore F508del cystic fibrosis transmembrane conductance regulator activity.
Summary
By fusing a CFTR-binding nanobody with cell-penetrating peptides, the authors achieved intracellular delivery into CF bronchial epithelial cells, stabilized misfolded F508del-CFTR, promoted its maturation/trafficking to the apical membrane, and restored chloride channel activity. The nanobody also potentiated the efficacy of approved CFTR modulators in primary patient airway cultures.
Key Findings
- Cell-permeable CFTR-binding nanobodies entered CF bronchial epithelial cells and primary airway cultures.
- Delivered nanobody stabilized misfolded F508del-CFTR, promoted maturation/trafficking to the apical membrane, and restored chloride channel function.
- Nanobody enhanced the efficacy of approved CFTR modulator combinations in primary patient airway epithelial cultures.
Clinical Implications
Although preclinical, this approach could complement or rescue suboptimal responses to CFTR modulators in patients with F508del, potentially expanding therapeutic options and addressing modulator non-responders.
Why It Matters
This is a first-in-class demonstration that cell-permeable nanobodies can correct a canonical intracellular folding/trafficking defect in CF and synergize with approved drugs, opening a new modality for respiratory genetic diseases.
Limitations
- Preclinical in vitro models without in vivo efficacy or safety data.
- Immunogenicity, dosing, and delivery optimization for human lungs remain undetermined.
Future Directions
Advance to in vivo lung delivery studies, assess immunogenicity/toxicology, optimize dosing and delivery vehicles, and design early-phase clinical trials, including combination with modulators in suboptimal responders.
Study Information
- Study Type
- Case series
- Research Domain
- Treatment/Pathophysiology
- Evidence Level
- V - Preclinical experimental mechanistic evidence from cell and primary tissue models.
- Study Design
- OTHER